drugset / Trial / NCT04844749
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
RandomizedParallel-groupSingle-blindTreatment
Summary
To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured by radiographic progression-free survival.
Timeline
- Start
- 2021-06-24
- Primary completion
- 2023-05-04
- Completion
- 2023-05-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abiraterone acetate | Small molecule | — | — |
| Comparator | Enzalutamide | Other / unclassified | — | — |
| Subject | Sabizabulin | Small molecule | 26 mg | Oral |
| Subject | Sabizabulin | Small molecule | 32 mg | Oral |